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Impaired fetal movement causes malformations, summarized as fetal akinesia deformation sequence (FADS), and is triggered by environ-
mental and genetic factors. Acetylcholine receptor (AChR) components are suspects becausemutations in the fetally expressed g subunit
(CHRNG) of AChR were found in two FADS disorders, lethal multiple pterygium syndrome (LMPS) and Escobar syndrome. Other AChR
subunits a1, b1, and d (CHRNA1, CHRNB1, CHRND) as well as receptor-associated protein of the synapse (RAPSN) previously revealed
missense or compound nonsense-missense mutations in viable congenital myasthenic syndrome; lethality of homozygous null muta-
tions was predicted but never shown.We provide the ﬁrst report to our knowledge of homozygous nonsense mutations in CHRNA1 and
CHRND and show that they were lethal, whereas novel recessive missense mutations in RAPSN caused a severe but not necessarily lethal
phenotype. To elucidate disease-associatedmalformations such as frequent abortions, fetal edema, cystic hygroma, or cardiac defects, we
studied Chrna1, Chrnb1, Chrnd, Chrng, and Rapsn in mouse embryos and found expression in skeletal muscles but also in early somite
development. This indicates that early developmental defects might be due to somite expression in addition to solely muscle-speciﬁc
effects. We conclude that complete or severe functional disruption of fetal AChR causes lethal multiple pterygium syndrome whereas
milder alterations result in fetal hypokinesia with inborn contractures or a myasthenic syndrome later in life.Introduction
Fetal movement is a precondition for normal fetal develop-
ment and growth. Depending on severity, intrauterine
movement restriction causes growth retardation, fetal hy-
drops, polyhydramnios, pulmonary hypoplasia, multiple
joint contractures with or without webbing (pterygia),
and other features, giving rise to the term fetal akinesia de-
formation sequence (FADS [MIM 208150]).1 Fetal akinesia
occurs in many genetic and acquired disorders. Examples
of environmental causes are curare exposure and circulat-
ing maternal antibodies against the fetal acetylcholine re-
ceptor.2–4 Restricted intrauterine space in twin pregnancies
or oligohydramnios also increases susceptibility. Genetic
entities include trisomy 18, myotonic dystrophies, central
core myopathy, and synaptopathies.5–9
Synaptopathies are diseases of the neuromuscular junc-
tion. Key molecules necessary for neuromuscular signal
transduction include presynaptic acetylcholine transferase
(CAT), acetylcholine esterase (AChE) in the synapse, and
postsynaptic muscular nicotinic acetylcholine receptor464 The American Journal of Human Genetics 82, 464–476, February(AChR). During fetal development, AChR consists of two
a1, one b1, one d, and one g subunit, whereas after 33
weeks gestation, the g subunit is replaced by an 3 subunit
(CHRNA1 [MIM100690], CHRNB1 [MIM100710], CHRND
[MIM 100720], CHRNG [MIM 100730], CHRNE [MIM
100725]).10 For neuromuscular signal transduction, all sub-
unitsmust be functional. In addition, theAChRmustbe cor-
rectly assembled, clustered, anchored, activated, and linked.
This complex process requires many contributing proteins
such as agrin (AGRN [MIM 103320]), muscle skeletal tyro-
sine kinase (MUSK [MIM 601296]), the muscle-intrinsic
activator of MUSK named DOK7 (downstream of tyrosine
kinase 7 DOK7 [MIM 610285]), and the receptor-associated
protein, rapsyn (RAPSN [MIM 601592]), that is involved in
AChR assembly and localization to the cell membrane
(Figure 1).11
Genetic disorders of the postsynaptic complex present as
recessively or dominantly inherited myasthenic syn-
dromes with variable age of onset and clinical severity.8,9,16
Mutations in the acetylcholine receptor g subunit cause
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Figure 1. Schematic View of AChR Complex
AChR at the postsynaptic membrane in muscle cells consist of 5
subunits.11 Two a1, one b1, one d subunit are always present.
The fifth subunit is the fetally expressed g subunit. By around 33
weeks of gestation in humans, g subunit expression is stopped
switching to 3, thereby replacing fetal-type AChR by adult-type
AChR.10 Rapsyn is a cytoskeletal membrane protein colocalizing
with AChR. Functionally, rapsyn is considered to transduce signals
from the agrin-activated MUSK. Not shown here, rapsyn connects
the receptor with the cytoskeletal dystrophin-glycoprotein-com-
plex (DGC) and stabilizes AChR clusters by interaction with cal-
pain.12–15The AmFADS spectrum, lethal multiple pterygium syndrome
(LMPS [MIM 253290]) and Escobar syndrome, a severe
condition with inborn contractures, pterygia, and respi-
ratory distress (MIM 265000).8,9 The AChR g subunit is
expressed in fetal development and is replaced by an 3
subunit in late gestation.10 The fetal CHRNG expression
explains the severe intrauterine phenotype with contrac-
tures, pterygia, and increased intrauterine lethality. The
physiological substitution of the g by the 3 subunit ex-
plains the absence of myasthenic symptoms after birth.
This g-3 switch is exceptional because the other AChR sub-
units a1, b1, and d do not have a substitute and remain
throughout fetal and adult life. Mutations in CHRNA1,
CHRNB1, CHRND, and RAPSN cause congenital myas-
thenic syndromes with muscular hypotonia or increased
fatigue later in life.16 The previously published patients ei-
ther had dominant myasthenic syndrome, recessive mis-
sense alterations, or compound genotypes of nonsense-
missense mutations in CHRNA1, CHRNB1, or CHRND.16
Lethality of homozygous null mutations in nonsubstituted
AChR subunits was predicted but never proven.16
We analyzed another 63 patients with lethal multiple
pterygium syndrome, Escobar syndrome, or other severe
forms of FADS but found CHRNG mutations in only three
of them. In the remaining 60 families, we suspected muta-
tions in other AChR pathway genes. We therefore se-
quenced the genes for rapsyn and for the other fetally ex-
pressed AChR subunits a1, b1, and d.Figure 2. Pedigrees of Described Families with CHRNA1, CHRND, or RAPSN Mutations Indicate Recessive Inheritance and
Increased Intrauterine Lethality
Two families with CHRNA1 mutations, two families with CHRND mutations causing lethal multiple pterygium syndrome, and one family
with recessive RAPSN mutations resulting in fetal akinesia syndrome with inborn contractures are shown. Arrow: index patient. Small
symbols represent abortions, intrauterine death, or termination of pregnancy because of severe affection.erican Journal of Human Genetics 82, 464–476, February 2008 465
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8Table 1. Clinical Features in Patients with Severe Fetal Akinesia Sequence
Family ID CHRNA1-F1 CHRNA1-F2 CHRND-F1 CHRND-F2
Family history of abortions yes (IV-2)   yes (II-3)
Patients, General Data
Patient ID CHRNA1-
F1; IV-1
CHRNA1-
F1; IV-3
CHRNA1-
F2; II-1
CHRNA1-
F2; II-2
CHRND-
F1; V-2
CHRND-
F1; V-3
CHRND-
F2; II-1
CHRND-
F2; II-2
CHRND-
F2; II-4
Gender M M ? M M M F F M
Sample for mutation
analysis
 þ  þ  þ   
Duration of pregnancy 24 gw 20 gw 28 gw 17 gw 15 gw 15 gw 23 gw 19 gw 12 gw
Current age stillbirth TP stillbirth TP TP TP died 2 d TP TP
Intrauterine Problems
Growth retardation þ þ NA þ þ þ NA NA NA
Edema/cystic hygroma þ/þ þ/þ NA þ/þ (7 gw) þ/NA þ/þ þ/NA NA/þ NA/þ
Decreased movements þ þ NA þ þ þ NA NA þ
Joint contractures þ þ NA þ þ þ NA þ þ
Poly/oligohydramnion   NA    NA NA NA
Postnatal or Autopsy Findings
Faciocranial dysmorphism þ þ NA þ NA NA NA þ NA
High arched palate NA NA NA  NA NA NA NA NA
Cleft palate þ þ NA  NA NA NA NA NA
Downslanting palpebral
fissures
NA NA NA þ NA NA NA NA NA
Hypertelorism NA NA NA NA NA NA NA þ NA
Depressed nasal bridge NA NA NA þ NA NA þ þ NA
Micrognathia þ NA NA þ NA NA NA þ NA
Low-set ears NA NA NA þ NA NA þ þ NA
Reduced muscle
bulk/hypoplasia
þ þ NA NA NA þ NA NA NA
Scoliosis þ þ NA  NA þ NA NA NA
Contractures þ þ NA þ NA þ NA þ þ
Pterygia þ þ NA þ NA þ (generalized
edema)
þ þ
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s.We report the ﬁrst homozygous nonsensemutations in the
two nonsubstituted subunits a1 and d that were indeed le-
thal. This shows that ﬁrst trimester fetal akinesia with hy-
drops, contractures, pterygia, and a fatal prognosis can be
due to recessive null mutations in CHRNA1 and CHRND
whereas novel recessive missense mutations in RAPSN
caused isolated fetal hypokinesia and contractures without
pterygia. We suggest that a spectrum of FADS phenotypes
ranging from recurrent spontaneous abortions and lethal
multiple pterygium syndrome (severe) to arthrogryposis
multiplex congenita (mild) are prenatal myasthenic syn-
dromes that warrant genetic and functional diagnostic
investigations of the AChR pathway.
Material and Methods
We studied 63 families referred for molecular genetic analysis of
FADS. Our ethics committee approved the study. Written, in-
formed consent was obtained from all participants or their legal
guardians.
We performed standard DNA sequencing.17 We sequenced cod-
ing regions of CHRNG initially and foundmutations in three of 63
families (data not shown). In the 60 remaining families, we ana-
lyzed coding regions of functional candidate genes CHRNA1,
CHRNB1, CHRND, and RAPSN. Primer sequences are available on
request. All newly identiﬁed mutations were tested for correct seg-
regation in the patient’s families and in 300 control chromosomes
to exclude a previously undescribed polymorphism. Standard se-
quencing procedures do not exclude disease-contributing muta-
tions in promoter regions, other regulatory elements, and exon
spanning deletions or inversions of the sequenced genes CHRNA1,
CHRNB1, CHRND, CHRNG, and RAPSN. However, the phenotypic
severity at least of the lethal phenotypes suggests more pro-
nounced effects than noncoding mutations would exercise by
modifying gene expression.
In Situ Hybridization
We generated probes for the a1, b1, and d subunits and for rapsyn
by RT-PCR frommouse E14.5 whole cDNA and received two other
probes for a1 and d from Bernhard Hermann and Heiner Schrewe
(MPI for Molecular Genetics, Berlin). Primer sequences are avail-
able on request. Antisense riboprobes were transcribed with SP6
or T7 polymerase with the Roche Dig-RNA labeling kit according
to the manufacturer’s instructions. Probes for AChR subunits g
and 3 as well as protocols for whole-mount in situ hybridizations
and in situ hybridizations on parafﬁn sections were previously
described.9,18,19
Results
Pedigrees of ﬁve families with positive mutation analysis
indicated recessive inheritance (Figure 2). Clinical charac-
teristics of these patients with new mutations are summa-
rized in Table 1. Prenatal ultrasound showed hypokinesia
and growth retardation. Frequent features were joint con-
tractures, cleft palate, and facial dysmorphism with low-
set ears, hypertelorism, and micrognathia. All affected in-
dividuals had reduced muscle mass compared to normallyThe American Journal of Human Genetics 82, 464–476, February 2008 467
Figure 3. Prenatal Ultrasound Revealed Fetal Hydrops and Contractures in Family CHRND-F1
Extensive generalized edema and flexion contractures of upper and lower limbs in individual V-3 from family CHRND-F1 were identified on
prenatal ultrasound at gestational week 13þ4 days. Edema separating skin from underlying structures extended from head and neck to
trunk and is marked by an asterisk.
(A) Pathologic nuchal edema extending down the back.
(B) Planum frontooccipitale with noticeable hygroma.
(C) Cross section through shoulder region reveals flexion contractures with adducted forearms and hands.
(D) Upper abdominal cross section shows extensive edema.
(E) Flexion contracture of lower limb with pes equines deformity.developed fetuses. Affected subjects in families CHRNA1-
F1/F2 and CHRND-F1/F2 had edema and pterygia (Figures
3 and 4). Joint contractures and pterygia affected upper
and lower extremities, variably, but predominantly shoul-
ders, elbows, wrists, hips, knees, and ankles were involved
(Figure 4). Occasionally, webbing between ﬁngers was de-
tected. Most affected fetuses did not reach term because
of spontaneous abortion, early intrauterine death, or preg-
nancy termination. If born alive, neonatal respiratory
distress was observed (preterm patient II-1 in family
CHRND-F2 and both patients from family RAPSN-F1).
Though restricted by tissue maceration, pathological ex-468 The American Journal of Human Genetics 82, 464–476, Februaramination revealed additional features such as hygroma
(CHRNA1-F1/F2, CHRND-F1/F2; Table 1 and Figure 4),
generalized hydrops (CHRNA1-F1/F2, CHRND-F1/F2;
Figures 3 and 4), pulmonary hypoplasia (CHRND-F2,
RAPSN-F1), and atrial septal defect (CHRND-F2).
We sequenced functional candidate genes CHRNA1,
CHRNB1, CHRND, and RAPSN in 60 families without
CHRNGmutations.We identiﬁed seven recessivemutations
in ﬁve families (Table 2). All mutations segregated with
disease and were not found in 300 control chromosomes.
Family CHRNA1-F1 revealed homozygosity for the mis-
sense mutation CHRNA1 c.761G/T predicted to causey 2008
Figure 4. CHRNA1 and CHRND Mutation-Positive Fetuses Presented with Massive Hydrops, Pterygia, and Contractures on Post-
mortem Examination whereas Novel Recessive Missense RAPSN Mutations Caused Congenital Arthrogryposis and Life-Threatening
Respiratory Distress
(A–F) Individual II-2 from family CHRNA1-F2 shows generalized edema most extreme at neck and head (gray arrowheads in [A] and [B]),
pterygia at elbows and knees (black arrowheads in [A] and [D]), and severe joint contractures (A, D–F) after induced abortion at 17
gestational weeks. X-ray reveals scoliosis, malformed head, and soft tissue swelling by nuchal hygroma (E, F).
(G–J) Individual V-3 from family CHRND-F1 is the same patient as in ultrasound Figure 3 and shown after induced abortion at gestational
age 14þ6. Generalized edema (gray arrowheads in [G] and [I]), pterygia at elbows and knees (black arrowheads in [G] and [H]), and
severe joint contractures (G–J) were detected on postmortem inspection. The fetogram (I, J) showed relatively broad clavicles, ribs,
and left metatarsal bone I, but did not reveal any severe skeletal anomalies.
(K–N) In contrast, patients with RAPSN mutations were born at term (family RAPSN-F1). Patient II-5 (K–M) was born with severe respi-
ratory problems and inborn contractures (L, M). Her affected brother II-4 (N) had similar clinical manifestations and deceased because of
respiratory insufficiency at the age of 10 months. Both patients had down-slanting palpebral fissures, mild hypertelorism, a wide nasal
bridge, low-set ears, micrognathia, and small mouth with tented lips (K, N).The American Journal of Human Genetics 82, 464–476, February 2008 469
Figure 5. Evolutionary Conservation of CHRNA1, CHRND, and RAPSN Missense Mutations
For all missense mutations, interspecies comparison reveals conservation in homolog positions in all mammals tested. CHRNA1 mutation
R234L (A) and both novel RAPSNmissense mutations (C, D) affect residues that show evolutionary conservation even beyond mammals. In
addition, residue of CHRNA1 mutation R234L (A) is also conserved in other human AChR subunits b1, d, g, and 3 as well as other a-type
subunits a2 and a3 in nonmuscular AChR.470 The American Journal of Human Genetics 82, 464–476, February 2008
Table 2. AChR Pathway Mutations in Families with Severe Fetal Akinesia Sequence
Family ID CHRNA1-F1 CHRNA1-F2 CHRND-F1 CHRND-F2 RAPSN-F1
Mutation in gene CHRNA1 CHRNA1 CHRND CHRND RAPSN
Location exon 6 exon 2 exon 3 exon 4/exon 12 exon 2/exon 3
Position cDNA c.761G/T
homozygous
c.117-133 dup17
homozygous
c.234G/A
homozygous
c.283T/C/c.1390C/T c.416T/C/c.566C/T
Residue in mature protein
(residue before cleavage of
signal peptide)
R234L (R254L in
precursor)
H25RfsX19
(H45RfsX19 in
precursor)
W57X (W78X in
precursor)
F74L/R443X
(F95L/R464X in
precursor)
F139S/A189V
Origin Pakistani African Turkish German Pakistani
Consanguinity þ  þ  
Included are lethal multiple pterygium, Escobar-like syndrome, and fetal akinesia with inborn arthrogryposis.amino acid substitution a1.R234L. Supporting the func-
tional relevance of position a1.R234L, this residue is com-
pletely conserved across species as well as in the homolo-
gous positions of the human b1, d, g, 3, a2, and a3
subunits (Figure 5A). In family CHRNA1-F2, the affected fe-
tus carried ahomozygousduplicationof 17basepairs c.117-
133 dup17 in CHRNA1, resulting in a frameshift mutation
with a subsequent premature stop codon (a1.H25RfsX19).
A homozygous nonsense mutation CHRND c.234G/A in
family CHRND-F1 introduced a premature stop (d.W57X).
Family CHRND-F2 is compound heterozygous for CHRND
mutations c.1390C/Tand c.283T/C. The former encode
the nonsense mutation d.R443X and the missense muta-
tion d.F74L. Residue d.F74L is conserved among mammals
(Figure 5B). Both patients from family RAPSN-F1 were
compound heterozygous for the RAPSN missense muta-
tions c.416T/C and c.566C/T, which encode F139S
and A189V, respectively. Both residues are conserved
across species, indicating functional relevance (Figures 5C
and 5D).
Patients with lethal multiple pterygium syndrome be-
cause of CHRNG mutations not only had severe prenatal
myasthenic symptoms, but also showed associated extra-
muscular ﬁndings such as generalized edema, nuchal hy-
groma, situs inversus, or cardiac defects.8,9 Extramuscular
manifestations could indicate disruptive effects in late em-
bryonic and early fetal development and also occurred in
individuals with the new CHRNA1, CHRND, and RAPSN
mutations described above. Therefore, we wanted to
know whether or not AChR subunit genes could contrib-
ute to earlier developmental processes. To study this ques-
tion, we analyzed the expression ofChrna1, Chrnb1, Chrnd,
Chrng, and Rapsn in mouse embryos before (E10.5, E11.5)
and during (E12.5, E14.5) muscle development as well as
in limb sections with advanced muscle development
(E15.5) (Figure 6). Interestingly, all studied subunits and
rapsyn are expressed in early somites as early as E10.5. At
E11.5, expression of Chrna1, Chrnb1, Chrnd, Chrng, and
Rapsn begins in the upper developing limb and seems toThe Amproceed proximal further into the developingmuscle bulks
at E12.5. At E14.5, expression corresponds to the muscle
anlagen in the trunk, neck, limbs, and diaphragm, con-
ﬁrming earlier studies.9,20 We also noticed strong expres-
sion of all analyzed subunit genes in the nuchal muscula-
ture, including those in close proximity to the jugular
lymphatic sac as well as in subcutaneous muscle layers
(Figures 6B and 6C).
Discussion
We identiﬁed the ﬁrst (to our knowledge) recessive null
mutations in the nonsubstituted AChR subunits a1 and
d. The reported CHRNA1 and CHRND mutations are null
mutations or affect evolutionary conserved amino acids
and caused lethal multiple pterygium syndrome. The
novel RAPSNmissense mutations were clinically associated
with inborn contractures and respiratory distress that was
lethal in one of the affected sibs. We found that Chrna1,
Chrnb1, Chrnd, Chrng, and Rapsn are expressed in somites
in early murine embryonic development and later also in
skeletal muscle. These ﬁndings support their pathogenic
relevance to FADS.
All patients with CHRNA1, CHRND, and RAPSN muta-
tions presented here had fetal akinesia, intrauterine growth
retardation, micrognathia, and contractures consistent
with fetal akinesia deformation sequence.1,5 We wondered
what distinguishes AChR pathway mutations causing a rel-
atively mild phenotype from other mutations with prena-
tal death and what factors contribute to the presence or ab-
sence of pterygia and the occurrence of additional ﬁndings
such as cardiac defects and pulmonary hypoplasia. CHRNG
mutations cause prenatal myasthenia that improves in late
pregnancy and does not progress or persist in surviving pa-
tients after birth.8,9 This is due to the physiological g to 3
switch around 33 weeks gestation in humans, when 3 be-
gins to function.10Mutations in genes encoding other com-
ponents of the postsynaptic AChR pathway should lead to(A) CHRNA1 R234L.
(B) CHRND F74L.
(C) RAPSN F139S.
(D) RAPSN A189V.erican Journal of Human Genetics 82, 464–476, February 2008 471
Figure 6. In Situ Hybridization in Mouse Embryos Reveals Early Expression of AChR Subunit Genes and Rapsn in Somites and Later
in Skeletal Muscle as well as in Hygroma-Relevant Regions
(A) Expression of Chrna1, Chrnb1, Chrnd, Chrng, and Rapsn in mouse development. Probes and embryonic stages are as indicated. E10.5,
E11.5, and E12.5 are shown as whole-mount in situ hybridization (ISH), E14.5 and E15.5 are shown as section-ISH. Chrna1, Chrnb1, Chrnd,
Chrng, and Rapsn are distinctly expressed in early somites as early as E10.5 (arrows), corresponding to human developmental age of 32
days (46 gestational day, Carnegie stage 14). At E11.5, expression of Chrna1, Chrnb1, Chrnd, Chrng, and Rapsn starts in upper developing472 The American Journal of Human Genetics 82, 464–476, February 2008
a phenotype that is more pronounced or even lethal be-
cause of lack of a substituting subunit for all other AChR
subunits. Our data conﬁrm this view.
Accordingly, the homozygous frameshift mutation
a1.H25RfsX19 in CHRNA1 in family CHRNA1-F2 predicts
a complete shutdown of fetal AChR function and was as-
sociated with intrauterine death. This ﬁnding is, to our
knowledge, the ﬁrst homozygous nonsense mutation re-
ported in this subunit. Severe edema was detected as early
as the 7th week of pregnancy and persisted to the 14th ges-
tational week when the pregnancy was terminated. Severe
fetal hydrops, extensive nuchal hygroma, and extreme
webbing were found. A homozygous missense mutation
a1.R234L caused a similar phenotype in family CHRNA1-
F1, indicating that a change of the evolutionary conserved
residue a1.R234 has the same lethal functional effect as the
nonsense mutation a1.H25RfsX19. In comparison, previ-
ously reported missense mutations in CHRNA1 cause via-
ble slow or fast channel congenital myasthenic syndrome
(CMS [e.g., MIM 60893, 601462, 254210]).21 A severely af-
fected female with fast channel myasthenic syndrome and
newborn respiratory distress harbored compound hetero-
zygosity for a truncating and a missense mutation
(CHRNA1.381 delC/a1.V132L).22 This patient might repre-
sent an intermediate type between milder myasthenic syn-
drome of postnatal onset and the severe prenatal effects we
observed in lethal multiple pterygium syndrome.
In the d subunit, our mutation d.W57X is, to our knowl-
edge, the ﬁrst reported homozygous truncating mutation
and causes a severe intrauterine phenotype with massive
edema, contractures, and pterygia in family CHRND-F1.
Family CHRND-F2 presented with an equally severe phe-
notype with spontaneous abortion, massive hydrops, pter-The Amygia, and pulmonary hypoplasia. The affected individuals
were compound heterozygous for nonsense mutation
d.R443X and missense mutation d.F74L. The mutations
in the d subunit reported here represent the severe end of
the spectrum. Other investigators have reported com-
pound heterozygosity for a missense and nonsense muta-
tion (d.E59K/d.756ins2) in a viable patient with inborn
contractures at an intermediate level, and a myasthenic
syndrome of postnatal onset with two other missense mu-
tations.23–25 Their patients likely represent the milder end
of the disease spectrum.
Our ﬁndings indicate that homozygosity for functional
null mutations of AChR subunits a1 and d, which are not
substituted in fetal development, causes a severe phenotype
with intrauterine hydrops, pterygia, and a high likelihood
for intrauterine death. Our data conﬁrm the hypothesis
that complete functional loss of nonsubstituted subunits
would be lethal.16 Althoughwe did not ﬁndCHRNB1muta-
tions in our patient sample, we postulate that this situation
also applies for recessive functional null mutations in the
b1 subunit that has a similar functional impact.
In comparison, the RAPSN missense mutations F139S
and A189V were associated with a milder phenotype
with inborn contractures and life-threatening respiratory
distress. Previously, only one patient with a homozygous
missense mutation other than N88K, namely R164C in
exon 2 of the RAPSN gene, presented with contractures,
muscular hypotonia, feeding, and respiratory problems.26
Thus, our mutations extend the spectrum of RAPSN mis-
sense mutations associated with congenital contractures.
Commonly, recessive RAPSN missense mutations cause
congenital myasthenic syndrome with associated AChR
deﬁciencywhereas compoundheterozygosity of amissenselimb and seems to further proceed from proximal into the developing muscle bulks at E12.5 days. At E14.5, expression corresponds to
muscle anlagen at trunk, neck, limbs, and diaphragm. Whereas Chrna1, Chrnb1, Chrng, and Rapsn are stably expressed throughout the
embryonic stages analyzed, Chrnd exhibits a more dynamic expression pattern. Chrnd shows strong expression in the posterior (newly
formed) somites at E10.5 and E11.5. Expression apparently decreases around E12.5, to barely detectable levels in whole-mount and sec-
tion in situ hybridization in somites (not shown). At E14.5, the muscles still show relatively weak expression. However, robust expression
is reappearing in differentiated muscles at E15.5.
Comparative developmental stages adapted from Wessels and Markwald.
Mouse E10.5z Carnegie stage 14z human developmental age of 32 days (post conception)z 46 days gestation (post menstruation)
Mouse E11.5z Carnegie stage 16z human developmental age of 37 days (post conception)z 51 days gestation (post menstruation)
Mouse E12.5z Carnegie stage 18z human developmental age of 44 days (post conception)z 58 days gestation (post menstruation)
Mouse E14.5 z Carnegie stage 23 z human developmental age of 54–56 days (post conception) z 68–70 days gestation (post
menstruation)
(B and C) Prenatal expression of AChR subunit genes and Rapsn in hygroma-relevant regions. Expression of a1 at E14.5 is representative
also for b1, d, and g (data not shown). Note strong expression in nuchal area, close proximity to jugular lymphatic sac (marked as ‘‘jls’’ in
higher magnification in [B]), and subcutaneous muscle layers (marked by an arrow in [C]). Mutations might contribute to edema by, for
example, decreased or absent muscle contractures and subsequently impaired transport of lymphatic fluid. The lymphatic system develops
from two structures. Deep parts of the jugular lymphatic sacs derive from tissue around jugular veins. Superficial parts of the jugular lym-
phatic sacs and peripheral lymphatic vessels develop from local lymphangioblasts originating from mesodermal anlagen.31–34 As long as
no connection is made between the jugular lymphatic sacs and the jugular veins, transient nuchal edema is physiological. If the lympho-
jugular junction connection is delayed and/or volume increases, abnormal nuchal edema or cystic hygroma occurs. A possible AChR-re-
lated pathomechanism for fetal edema is that defective neuromuscular signal transduction causes lack of muscle contractions and thus
impairs lymphatic fluid movement. Other potential mechanisms include altered muscle development affecting subsequent development
and differentiation of lymphatic vessels. Finally, both muscle and lymphatic anlagen may depend on similar AChR-related signals or com-
ponents. AChR and rapsyn expression in premuscular and muscular tissues and close anatomical proximity to lymphatic structures both in
embryonic development and fetal differentiation is consistent with this view.erican Journal of Human Genetics 82, 464–476, February 2008 473
and a truncating defect were associated with contrac-
tures.16,26–29
We were curious what differentiates mutations present-
ing with pterygia from those that only reduce intrauterine
movements and cause contractures, because impaired fetal
movement seems to trigger both contractures and ptery-
gia. In our families, hypokinesia and contractures were ﬁrst
detected by ultrasound at 11–14 weeks of gestation. At that
time, pterygia in patients with CHRNA1 or CHRND muta-
tions were already visible at postmortem examination.
The onset of pterygia is therefore likely to occur earlier.
In family CHRNA1-F2, fetal hydrops and cystic nuchal hy-
groma appeared on ultrasound in the 7th gestational week;
the fetus later presented with severe webbing (Figure 4). In
this case, fetal edema could have predisposed to subse-
quent webbing. A pathogenic association of pterygia with
previous fetal edema has long been suspected.30 This no-
tion is supported by observations in our families.
Mutations in AChR subunit genes are also associated
with developmental anomalies in other tissues that are
not primarily associated with neuromuscular junctions.8,9
Cardiac defects, renal malformation, and intestinal malro-
tation are features of the lethal multiple pterygium syn-
drome.1,5 We observed edema, cardiac defects, and pulmo-
nary hypoplasia in our patients. This association indicates
that the mutations might interfere with normal embryo-
genesis. Our in situ data show expression not only in later
developmental stages when muscle differentiation is evi-
dent, but also in early developmental stages as demon-
strated in mouse E10.5. Mouse developmental stage
E10.5 corresponds to human developmental day 32, at
which time Chrna1, Chrnb1, Chrnd, Chrng, and Rapsn are
expressed in early somites. Somites are segmental regions
wheremesodermal structures develop in the trunk. This in-
dicates that mutations in the AChR subunit genes may
have an effect on early mesodermal structures such as mus-
cle anlagen. Also, peripheral lymphangioblasts are the or-
ganizers for lymphatic vessels in extremities and develop
from these regions in the somites.31–35 Thus, very early pre-
natal ﬁndings, such as frequent abortions or generalized
edema, could be attributed to a defect of early AChR sub-
unit expression in somites in addition to muscle-speciﬁc
effects alone. However, at this point the evidence is specu-
lative, because so far no role for AChR expression has been
demonstrated in early embryonic development or meso-
dermal differentiation. In later developmental stages, the
classical function of AChR in establishing, maintenance,
and signal transduction of neuromuscular junctions might
contribute to hypokinesia and growth retardation.
Accordingly, other genes encoding AChR pathway com-
ponents may harbor mutations in FADS patients without
mutations in AChR subunits or RAPSN. AChR-related
candidates are Agrin, MUSK, ARIA, the postsynaptic cyto-
skeletal components dystroglycan and actin, as well as
a growing number of more or less direct contributors
such as recently reported for CDK5, calpain, DOK7, and
ACF7.11,15,36–41474 The American Journal of Human Genetics 82, 464–476, FebruaAwareness of the variable clinical presentation of AChR
pathway mutations might be life-saving, as in our family
RAPSN-F1. At birth, both affected children had arthrogry-
posis but were not diagnosed for neuromuscular transmis-
sion defects. After identiﬁcation of RAPSN mutations, the
surviving child was started on AChE inhibitors (4 3 1
mg/kg/d Mestinone). Her motor function and hypotonia
improved signiﬁcantly. However, feeding problems have
been persisting; a percutaneous endoscopic gastrostomy
(PEG) tube is still required. The positive therapeutic effect
was even more obvious when the patient had to be admit-
ted to the ICU because of an infection-triggered myas-
thenic crisis with a decrease of capillary O2 saturation to
60% and respiratory acidosis. Remarkably, only 1 day after
increasing the dose of Mestinone to 6 mg/kg/d, her symp-
toms and respiratory parameters improved to an extent
that she could leave the ICU. After her infection and the
subsequent stop of the antibiotic treatment, the dose of
Mestinone was reduced back to the initial 4 mg/kg/d with-
out any side effects. This underlines the therapeutic rele-
vance of early clinical and genetic consideration of AChR
pathway mutations.
We conclude that AChR pathway mutations are relevant
for a wide FADS disease spectrum. Our results conﬁrm the
idea that fetal akinesia predisposes to the development of
contractures. Additional ﬁrst trimester fetal edema seems
to predispose to pterygia development. Consequently,
the AChR pathway contributes to a broad spectrum of in-
trauterine phenotypes and should be examined function-
ally and genetically in patients with recurrent spontaneous
abortions, fetal akinesia, hydrops, pterygia, or inborn
contractures.
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